This channel includes news on cardiovascular care delivery, including how patients are diagnosed and treated, cardiac care guidelines, policies or legislation impacting patient care, device recalls that may impact patient care, and cardiology practice management.
There’s no shortage of resources for healthcare workers who wish they knew AI well enough to talk shop with the technology pros who develop the models. The problem is weeding through the offerings to get to what will really work for you.
Discussions of AI governance may cause many an eye to glass over, but the discipline is as crucial to the ascent of AI in healthcare as big training datasets drawn from diverse patient populations.
For whatever reason, the grownups seem to get all the attention when talk turns to AI in healthcare. All the kiddos get to do is look on and listen in. Now comes a worthy little effort to balance the seesaw.
Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more.
The aim of the biotech company is to “transform healthcare by providing comprehensive information on patient predisposition to disease, disease prevention and personalized intervention and treatments."
WalletHub ranked which states are the best for doctors, looking at 19 key metrics, including wages, number of hospitals, population rate, competition and more.
In the last few years, uninsured rates dropped to a historic low of 8%, while racial disparities across healthcare have also vastly improved, according to a new report from the Commonwealth Fund.
Cynthia Rudin, PhD, is a highly regarded computer scientist who’s been eyeing the advance of artificial intelligence into society with equal parts enthusiasm and concern.
The Medicare Prescription Drug Inflation Rebate Program will lower coinsurance for Medicare Part B beneficiaries for certain drugs, with savings between $2 and $390 per average dose starting April 1.
When human counselors are unavailable to provide work-based wellness coaching, robots can substitute—as long as the workers are comfortable with emerging technologies and the machines aren’t overly humanlike.
Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more.
Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.
When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country.